Cat. No.: HY-N0488

Vincristine sulfate

(Synonyms: Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate)

75 Cited Publications

Customer Review

Based on 75 publication(s) in Google Scholar

Vincristine (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) sulfate is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a K_i of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.

For research use only. We do not sell to patients.

Purity: 99.43%
CAS No.: 2068-78-2
Formula: C₄₆H₅₈N₄O₁₄S
Molecular Weight:923.04

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Vincristine sulfate Chemical Structure

CAS No.: 2068-78-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (75)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	IC₅₀	>100 μM Compound: Vincristine	Cytotoxic activity against human tumor A-172 cell line Cytotoxic activity against human tumor A-172 cell line	[PMID: 15857148]
A549	IC₅₀	171.5 nM Compound: Vincristine sulphate	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28038323]
A549	IC₅₀	20 nM Compound: Vincristine sulfate	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
ARO	IC₅₀	<0.0001 μM Compound: Vincristine	Cytotoxic activity against human tumor Aro cell line Cytotoxic activity against human tumor Aro cell line	[PMID: 15857148]
BT-549	IC₅₀	54.72 nM Compound: Vincristine sulphate	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay	[PMID: 28038323]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human CNS cancer cell by NCI-CLS assay Growth inhibition of human CNS cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human colon cancer cell by NCI-CLS assay Growth inhibition of human colon cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human prostate cancer cell by NCI-CLS assay Growth inhibition of human prostate cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human colon cancer cells after 48 hrs Growth inhibition of human colon cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human colon cancer cells after 48 hrs Cytotoxicity against human colon cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human CNS cancer cells after 48 hrs Growth inhibition of human CNS cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Growth inhibition of human prostate cancer cells after 48 hrs Growth inhibition of human prostate cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human CNS cancer cells after 48 hrs Cytotoxicity against human CNS cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.13 μM Compound: Vincristine sulfate	Cytotoxicity against human prostate cancer cells after 48 hrs Cytotoxicity against human prostate cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human breast cancer cell by NCI-CLS assay Growth inhibition of human breast cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human ovarian cancer cell by NCI-CLS assay Growth inhibition of human ovarian cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.3 μM Compound: Vincristine sulfate	Growth inhibition of human renal cancer cell by NCI-CLS assay Growth inhibition of human renal cancer cell by NCI-CLS assay	[PMID: 20395150]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human breast cancer cells after 48 hrs Growth inhibition of human breast cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human Ovarian cancer cells after 48 hrs Growth inhibition of human Ovarian cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Growth inhibition of human renal cancer cells after 48 hrs Growth inhibition of human renal cancer cells after 48 hrs	[PMID: 20684599]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 22283430]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human breast cancer cells after 48 hrs Cytotoxicity against human breast cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human ovarian cancer cells after 48 hrs Cytotoxicity against human ovarian cancer cells after 48 hrs	[PMID: 24747749]
Cancer cell lines	GI₅₀	0.32 μM Compound: Vincristine sulfate	Cytotoxicity against human renal cancer cells after 48 hrs Cytotoxicity against human renal cancer cells after 48 hrs	[PMID: 24747749]
DU-145	IC₅₀	71.83 μM Compound: Vincristine sulphate	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
DU-145	IC₅₀	72.3 nM Compound: Vincristine sulphate	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28038323]
HEK293	IC₅₀	31 nM Compound: Vincristine sulfate	Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HeLa	IC₅₀	0.0358 μM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
HeLa	IC₅₀	36 nM Compound: Vincristine sulfate	Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay	[PMID: 23215348]
HepG2	IC₅₀	0.1 μM Compound: Vincristine	Cytotoxic activity against human tumor Hep G2 cell line Cytotoxic activity against human tumor Hep G2 cell line	[PMID: 15857148]
HepG2	IC₅₀	0.69 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 26522953]
HL-60	IC₅₀	11.2 μg/mL Compound: vincristine sulfate	Cytotoxicity against human HL60 cells after 48 hrs Cytotoxicity against human HL60 cells after 48 hrs	[PMID: 17432904]
HT-29	IC₅₀	0.1 μM Compound: Vincristine	Cytotoxic activity against human tumor HT-29 cell line Cytotoxic activity against human tumor HT-29 cell line	[PMID: 15857148]
IGROV-1	IC₅₀	0.01 μM Compound: Vincristine	Cytotoxic activity against human tumor Igrov-1 cell line Cytotoxic activity against human tumor Igrov-1 cell line	[PMID: 15857148]
KB	IC₅₀	0.02 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 26522953]
L02	IC₅₀	28.4 μg/mL Compound: vincristine sulfate	Cytotoxicity against human L02 cells after 48 hrs Cytotoxicity against human L02 cells after 48 hrs	[PMID: 17432904]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Growth inhibition of human leukemia cell by NCI-CLS assay Growth inhibition of human leukemia cell by NCI-CLS assay	[PMID: 20395150]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Growth inhibition of human leukemia cells after 48 hrs Growth inhibition of human leukemia cells after 48 hrs	[PMID: 20684599]
Leukemia cell	GI₅₀	0.1 μM Compound: vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 22283430]
Leukemia cell	GI₅₀	0.1 μM Compound: Vincristine sulfate	Cytotoxicity against human leukemia cells after 48 hrs Cytotoxicity against human leukemia cells after 48 hrs	[PMID: 24747749]
LNCaP	IC₅₀	0.0029 μM Compound: Vincristine sulphate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 20732809]
LNCaP	IC₅₀	6.1 nM Compound: Vincristine sulfate	Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay	[PMID: 23215348]
Lu1	IC₅₀	0.48 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 26522953]
MCF7	IC₅₀	0.01 μM Compound: Vincristine	Cytotoxic activity against human tumor MCF-7 cell line Cytotoxic activity against human tumor MCF-7 cell line	[PMID: 15857148]
MCF7	IC₅₀	0.51 μM Compound: 2; VCR.H2SO4	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 26522953]
MDA-MB-231	IC₅₀	116.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28038323]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Growth inhibition of human melanoma cells after 48 hrs Growth inhibition of human melanoma cells after 48 hrs	[PMID: 20684599]
Melanoma cell	GI₅₀	0.16 μM Compound: vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 22283430]
Melanoma cell	GI₅₀	0.16 μM Compound: Vincristine sulfate	Cytotoxicity against human melanoma cells after 48 hrs Cytotoxicity against human melanoma cells after 48 hrs	[PMID: 24747749]
Melanoma cell	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human melanoma cell by NCI-CLS assay Growth inhibition of human melanoma cell by NCI-CLS assay	[PMID: 20395150]
NFF	IC₅₀	0.0169 μM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
NFF	IC₅₀	17 nM Compound: Vincristine sulfate	Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay	[PMID: 23215348]
NSCLC	GI₅₀	0.2 μM Compound: Vincristine sulfate	Growth inhibition of human NSCLC cell by NCI-CLS assay Growth inhibition of human NSCLC cell by NCI-CLS assay	[PMID: 20395150]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Growth inhibition of human NSCLC cells after 48 hrs Growth inhibition of human NSCLC cells after 48 hrs	[PMID: 20684599]
NSCLC	GI₅₀	0.25 μM Compound: vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 22283430]
NSCLC	GI₅₀	0.25 μM Compound: Vincristine sulfate	Cytotoxicity against human NSCLC cells after 48 hrs Cytotoxicity against human NSCLC cells after 48 hrs	[PMID: 24747749]
OVCAR-3	IC₅₀	0.01 μM Compound: Vincristine	Cytotoxic activity against human tumor Ovcar-3 cell line Cytotoxic activity against human tumor Ovcar-3 cell line	[PMID: 15857148]
PC-3	IC₅₀	0.011 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 20732809]
PC-3	IC₅₀	0.0153 μM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 23489291]
PC-3	IC₅₀	15 nM Compound: Vincristine sulfate	Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay	[PMID: 23215348]
PC-3	IC₅₀	27.6 nM Compound: Vincristine sulphate	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28038323]
PC-3	IC₅₀	28.11 μM Compound: Vincristine sulphate	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
SMMC-7721	IC₅₀	26.7 μg/mL Compound: vincristine sulfate	Cytotoxicity against human SMMC7721 cells after 48 hrs Cytotoxicity against human SMMC7721 cells after 48 hrs	[PMID: 17432904]

In Vitro

Vincristine sulfate (100 nM; 0-48 h) induces apoptosis in G1-phase enriched ALL-2 and ALL-5 cells without mitotic arrest (no MPM2 staining); it also induces apoptosis in G2-M phase enriched ALL-2 and ALL-5 cells in the presence of mitotic arrest (enhanced MPM2 staining)^[2].
Acute treatment with Vincristine sulfate (1 μM; 2 h) inhibits the proliferation of B16 melanoma cells, and its potency is lower than that of vinblastine (HY-13780) and vindesine (HY-16514)^[4].
Vincristine sulfate (5-2000 nM; 24-48 h) induces mRNA expression of ABCC2, ABCC3, PXR and CYP3A4 (10 nM, 48 h) in LS174T and A549 cells, and regulates the expression of ABCB1 and ABCC2 in Caco2 cells in a concentration- and time-dependent manner^[5].
Treatment of SGC7901 cells with Vincristine sulfate (0.5-1.5 μg/mL) upregulates the mRNA expression of Snail, Twist, MRP and Pgp, indicating that the epithelial-mesenchymal transition and multidrug resistance pathways are activated^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vincristine (5-10 mg/kg; i.v.) sulfate induces significant tumor necrosis and reduces tumor blood flow in mice subcutaneously implanted with colon 38 adenocarcinoma^[3].
Vincristine (10 mg/kg; i.p.) sulfate induces significant tumor necrosis in subcutaneous multidrug-resistant P388 leukemia subline xenografts in mice^[3].
Vincristine (75 μg/kg; i.p.; daily; 10 days) sulfate induces peripheral neuropathic pain in mice, which is characterized by behavioral, electrophysiological, histopathological, oxidative stress and inflammatory changes^[7].
Vincristine (0.1 mg/kg; i.p.; daily; 7 days) sulfate induces dose- and duration-dependent peripheral neuropathic pain and oxidative stress in mice^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 2068-78-2
Appearance Solid
Molecular Weight 923.04
Formula C₄₆H₅₈N₄O₁₄S
Color White to off-white
SMILES

CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O
Synonyms

Leurocristine sulfate; NSC-67574 sulfate; 22-Oxovincaleukoblastine sulfate
Structure Classification
- Alkaloids
- Alkaloid Dimers
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (75)

All IFCell Proliferation/Viability AssayApoptosis AnalysisWB

Sort by:

Journal Impact Factor

Nature

Catabolism of extracellular glutathione supplies cysteine to support tumours. [Abstract]

2026 May;653(8115):933-941. PMID: 41851454
Cell

SARM1 senses dsDNA to promote NAD+ degradation and cell death. [Abstract]

2025 Dec 11;188(25):7137-7154.e21. PMID: 41138726

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Cell. 2025 Dec 11;188(25):7137-7154.e21. [Abstract]

Representative IF images showing the colocalization between mSARM1 and the noted chemo-induced cytosolic dsDNA in neural cells. The noted neural cells were treated with 20 μM CP, 100 μM CBP, or 0.5 μM VCR (Vincristine) for 36 h, followed by IF analyses. Green: dsDNA stained with anti-dsDNA antibody; red: mSARM1 stained with anti-SARM1 antibody; blue: DAPI. Scale bar, 10 μm.
Cell

Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. [Abstract]

2024 Apr 25;187(9):2288-2304.e27. PMID: 38565142
Mol Cancer

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]

2024 Jan 10;23(1):12. PMID: 38200517
Cancer Commun (Lond)

N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer. [Abstract]

2024 Apr;44(4):469-490. PMID: 38512764

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Apr;44(4):469-490. [Abstract]

IC₅₀ values of SGC7901^VCR shNC and SGC7901^VCR shA2B1 cells treated with VCR (Vincristine, 0.1-100 µg/mL; 48 h) and 5‐Fu (0.1-100 µg/mL; 48 h).

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 Apr;44(4):469-490. [Abstract]

Apoptosis of SGC7901^VCRshNC and SGC7901^VCR shA2B1 cells treated with VCR (Vincristine, 1 or 15 µg/mL; 48 h) and 5‐Fu (1 or 20 µg/mL; 48 h).
Drug Resist Updat

Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance. [Abstract]

2023 Feb 13;68:100951. PMID: 36841134
Cell Mol Immunol

Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]

2023 Jan;20(1):51-64. PMID: 36447031

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]

Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
Nat Commun

RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance. [Abstract]

2026 Jan 12;17(1):162. PMID: 41526341
J Clin Invest

DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]

2024 Mar 7;134(10):e172716. PMID: 38451729

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]

The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
Leukemia

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness. [Abstract]

2021 Oct;35(10):2827-2839. PMID: 33782537

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]

TF-1 derivative cell lines were incubated with the indicated concentrations of vincristine (20 nM) or Regorafenib (10 μM) for 2 days, and the proportions of apoptotic cells were determined by staining with AnnexinV. Mean + SEM, n = 3.
Sci Adv

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. [Abstract]

2023 Feb 10;9(6):eade9238. PMID: 36753540
Mol Ther

Exosomal miR-1246 from glioma patient body fluids drives the differentiation and activation of myeloid-derived suppressor cells. [Abstract]

2021 Dec 1;29(12):3449-3464. PMID: 34217892
MedComm (2020)

KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]

2025 Nov 29;6(12):e70517. PMID: 41328326
Cell Rep Med

Single-cell profiles delineate immune cell remodeling and enhanced tumor-fibroblast interaction of hepatoblastoma after chemotherapy. [Abstract]

2025 Oct 21;6(10):102401. PMID: 41038160
Cell Rep Med

scRNA-seq reveals an immune microenvironment and JUN-mediated NK cell exhaustion in relapsed T-ALL. [Abstract]

2025 Apr 25:102098. PMID: 40306275
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. [Abstract]

2024 Mar 19;5(3):101468. PMID: 38508144
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587
Cell Death Dis

Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]

2025 Mar 12;16(1):170. PMID: 40075071
Proc Natl Acad Sci U S A

Selective inhibitors of SARM1 targeting an allosteric cysteine in the autoregulatory ARM domain. [Abstract]

2022 Aug 30;119(35):e2208457119. PMID: 35994671
Cell Commun Signal

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]

2024 Jun 13;22(1):325. PMID: 38872211
Int J Biol Macromol

Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer. [Abstract]

2019 May 1:128:574-582. PMID: 30710584

Vincristine sulfate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2019 May 1:128:574-582. [Abstract]

SGC7901/DDP or SGC7901/VCR (Vincristine) cells are transfected with si-Con or si-ERK, and transfection efficiency is evaluated by western blot assay at 48 h post transfection.
Acta Pharmacol Sin

A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects. [Abstract]

2024 Oct;45(10):2174-2185. PMID: 38844788
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Cancer Immunol Res

Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]

2023 May 3;11(5):583-599. PMID: 36921097
J Transl Med

Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. [Abstract]

2023 Jan 9;21(1):9. PMID: 36624452
Biomed Pharmacother

Mitoquinone alleviates vincristine-induced neuropathic pain through inhibiting oxidative stress and apoptosis via the improvement of mitochondrial dysfunction. [Abstract]

2020 May;125:110003. PMID: 32187955
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Cell Chem Biol

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]

2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904
Cell Rep

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. [Abstract]

2026 Mar 17:117063. PMID: 41850280
J Med Chem

Structure-Based Discovery of Imidazo[4,5- c]pyridine SARM1 Modulators Showing Paradoxical Activation. [Abstract]

2026 Apr 23;69(8):9521-9536. PMID: 41948869
Clin Transl Med

IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]

2025 May;15(5):e70336. PMID: 40356256
Br J Cancer

DRD4 promotes chemo-resistance and cancer stem cell-like phenotypes by mediating the activation of the Akt/β-catenin signaling axis in liver cancer. [Abstract]

2024 Oct;131(7):1212-1223. PMID: 39174739
Int J Nanomedicine

Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance. [Abstract]

2017 Mar 16:12:2081-2108. PMID: 28356731
Ind Crops Prod

2025 Aug.
Eur J Med Chem

Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. [Abstract]

2018 Feb 25:146:157-170. PMID: 29407947
Cells

A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]

2026 Feb 23;15(4):383. PMID: 41744826
Drug Des Devel Ther

Vincristine Regulates C/EBP-β/TGF-β1 to Promote A1 Astrocyte Polarization and Induce Neuropathic Pain. [Abstract]

2025 Feb 7:19:827-840. PMID: 39935576
Front Pharmacol

RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma. [Abstract]

2022 Jul 15:13:931501. PMID: 35910358
Cancer Biol Ther

Identification of coilin in bone marrow as a potential neuroblastoma tumor progression marker transcriptionally regulated by MYCN. [Abstract]

2026 Dec 31;27(1):2600709. PMID: 41423806
J Biomed Inform

From Centralized to Ad-Hoc Knowledge Base Construction for Hypotheses Generation. [Abstract]

2023 Jun:142:104383. PMID: 37196989
Mol Pharm

Machine Learning Models Identify New Inhibitors for Human OATP1B1. [Abstract]

2022 Nov 7;19(11):4320-4332. PMID: 36269563
Front Microbiol

Rice Yellow Stunt Nucleorhabdovirus Matrix Protein Mediates Viral Axonal Transport in the Central Nervous System of Its Insect Vector. [Abstract]

2019 May 9:10:939. PMID: 31143161
Clin Epigenetics

Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]

2025 May 6;17(1):77. PMID: 40329330
Cancers (Basel)

Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]

2022 Oct 19;14(20):5127. PMID: 36291909
Cancers (Basel)

miR-92b-3p Regulates Cell Cycle and Apoptosis by Targeting CDKN1C, Thereby Affecting the Sensitivity of Colorectal Cancer Cells to Chemotherapeutic Drugs. [Abstract]

2021 Jul 2;13(13):3323. PMID: 34283053
Sci Rep

Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. [Abstract]

2019 Aug 12;9(1):11677. PMID: 31406154
Front Oncol

Hypoxanthine in the microenvironment can enable thiopurine resistance in acute lymphoblastic leukemia. [Abstract]

2024 Jul 19:14:1440650. PMID: 39099696
Front Oncol

Adipocytes Provide Fatty Acids to Acute Lymphoblastic Leukemia Cells. [Abstract]

2021 Apr 22:11:665763. PMID: 33968771
Front Oncol

Regulation of Integrin Subunit Alpha 2 by miR-135b-5p Modulates Chemoresistance in Gastric Cancer. [Abstract]

2020 Mar 13;10:308. PMID: 32232000
Hum Exp Toxicol

Effect of fenofibrate on proliferation of SMMC-7721 cells via regulating cell cycle. [Abstract]

2021 Jul;40(7):1208-1221. PMID: 33538198
Breast Cancer Res Treat

Organoid models derived from patients with malignant phyllodes tumor of the breast. [Abstract]

2023 Jul;200(2):193-201. PMID: 37204665
Am J Cancer Res

Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. [Abstract]

2021 Apr 15;11(4):1428-1445. PMID: 33948366
J Chromatogr B Analyt Technol Biomed Life Sci

Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. [Abstract]

2021 Apr 1:1168:122591. PMID: 33684722
S Afr J Bot

2026 Feb 9.
SLAS Discov

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3. [Abstract]

2024 Feb 12;29(2):100147. PMID: 38355016
Biochem Biophys Res Commun

Identification of VPS34-PI(3)P-FEN1-mediated DNA repair pathway as a potential drug target to overcome chemoresistance. [Abstract]

2023 Sep 24:674:27-35. PMID: 37393641
Leuk Lymphoma

Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia. [Abstract]

2020 Feb;61(2):420-428. PMID: 31526067
Neurobiol Learn Mem

Role of microtubules in late-associative plasticity of hippocampal Schaffer collateral-CA1 synapses in mice. [Abstract]

2019 Sep:163:107038. PMID: 31278986
bioRxiv

2026 Jan 9.
bioRxiv

2026 Jan 13.
bioRxiv

2025 Sep 21.
bioRxiv

MCL1 may not mediate chemoresistance. [Abstract]

2025 Aug 27:2025.08.22.671824. PMID: 40909578
Cell Biomater

2025 Jul 22.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
SSRN

2025 Jun 4.
Cairo University

2025.
bioRxiv

2024 July 04.
bioRxiv

An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. [Abstract]

2024 Jul 22:2023.09.14.557413. PMID: 39091882
bioRxiv

Activation of the mevalonate pathway in response to anti-cancer treatments drives glioblastoma recurrences through activation of Rac-1. [Abstract]

2023 Jul 25:2023.07.23.550205. PMID: 37546917
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363
bioRxiv

2023 Apr 14.
bioRxiv

Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. [Abstract]

2023 Feb 27:2023.02.27.530263. PMID: 36909518
bioRxiv

2019 Dec.
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827

Solvent & Solubility

In Vitro:

DMSO : 350 mg/mL (379.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (54.17 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0834 mL

5.4169 mL

10.8338 mL

5 mM

0.2167 mL

1.0834 mL

2.1668 mL

10 mM

0.1083 mL

0.5417 mL

1.0834 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 4.17 mg/mL (4.52 mM); Clear solution

This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 4.17 mg/mL (4.52 mM); Clear solution

This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 4.17 mg/mL (4.52 mM); Clear solution

This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (108.34 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Cell Assay^[1]

Cells are plated in 2 mL of medium in 35 mm plates at a concentration of about 5×10⁴ cells/mL and grow for 24 h at 37°C in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (291 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Douer D, et al. Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia. Oncologist. 2016;21(7):840-847. [Content Brief]

[2]. Kothari A, et al. Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells. Cancer Res. 2016;76(12):3553-3561. [Content Brief]

[3]. Baguley BC, et al. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482-487. [Content Brief]

[4]. Jordan MA, et al. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985;45(6):2741-2747. [Content Brief]

[5]. Huang R, et al. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006;71(12):1695-1704. [Content Brief]

[6]. Xue Z, et al. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. J Cell Biochem. 2012;113(1):302-312. [Content Brief]

[7]. Gong SS, et al. Neuroprotective Effect of Matrine in Mouse Model of Vincristine-Induced Neuropathic Pain. Neurochem Res. 2016;41(11):3147-3159. [Content Brief]

[8]. Babu A, et al. Effect of curcumin in mice model of vincristine-induced neuropathy. Pharm Biol. 2015;53(6):838-848. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.0834 mL	5.4169 mL	10.8338 mL	27.0844 mL
	5 mM	0.2167 mL	1.0834 mL	2.1668 mL	5.4169 mL
	10 mM	0.1083 mL	0.5417 mL	1.0834 mL	2.7084 mL
	15 mM	0.0722 mL	0.3611 mL	0.7223 mL	1.8056 mL
	20 mM	0.0542 mL	0.2708 mL	0.5417 mL	1.3542 mL
	25 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0834 mL
	30 mM	0.0361 mL	0.1806 mL	0.3611 mL	0.9028 mL
	40 mM	0.0271 mL	0.1354 mL	0.2708 mL	0.6771 mL
	50 mM	0.0217 mL	0.1083 mL	0.2167 mL	0.5417 mL
DMSO	60 mM	0.0181 mL	0.0903 mL	0.1806 mL	0.4514 mL
	80 mM	0.0135 mL	0.0677 mL	0.1354 mL	0.3386 mL
	100 mM	0.0108 mL	0.0542 mL	0.1083 mL	0.2708 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Vincristine sulfate

75 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Vincristine sulfate

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Chemotherapy Drug Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Anti-Aging Natural Product Library

Heterocyclic Compound Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Vincristine sulfate

Biological Activity

Chemical Information

Publications (75)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Vincristine sulfate Related Classifications

Cat. No.: HY-N0488